LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a ...

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that affects somewhere between 4 and 40 people per million worldwide. The condition causes substances such as fats and proteins ...

The sisters that Neehus studied had several lung abnormalities: a history of respiratory infections, polycystic lung disease, and pulmonary alveolar proteinosis (PAP), a disorder characterized by lung ...

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price ...

Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was ...

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

at 08:40 Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research ...